Estrogen signaling pathway and hormonal therapy

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Hormonal therapies, including luteinizing hormone-releasing hormone (LH-RH) agonists, selective estrogen receptor modulators (SERMs), and aromatase inhibitors, are advancing for cancer treatment.
• Current biomarkers like estrogen receptor (ER) and progesterone receptor (PgR) have limitations in predicting individual response to endocrine therapy.
• Discrepancies in treatment outcomes, such as resistance to aromatase inhibitors, suggest underlying molecular mechanisms beyond ER status.

Purpose of the Study:

• To explore the molecular mechanisms driving differential responses to hormonal therapies in breast cancer.
• To investigate the role of estrogen-related intracellular signaling pathways in treatment efficacy and resistance.
• To discuss current and future strategies for predicting individual hormonal therapy effectiveness.

Main Methods:

• Review of current literature on hormonal therapies and breast cancer signaling pathways.
• Analysis of molecular mechanisms underlying variable patient responses to endocrine treatments.
• Discussion of predictive biomarkers and novel therapeutic strategies.

Main Results:

• Estrogen receptor alpha (ERalpha)-positive patients exhibit variable responses to endocrine therapy, with approximately one-third not responding.
• Some ERalpha-negative patients paradoxically respond to endocrine therapy.
• Intracellular estrogen signaling pathways and mechanisms of aromatase inhibitor resistance contribute to treatment ineffectiveness.

Conclusions:

• Individual efficacy of hormonal therapy is influenced by complex intracellular estrogen signaling pathways, not solely ER status.
• Understanding these pathways is crucial for overcoming endocrine resistance and improving treatment outcomes.
• Further research into molecular mechanisms will enable better prediction of hormonal therapy efficacy and development of personalized treatment strategies.